Neuroleptic Malignant Syndrome (NMS) is a rare, potentially fatal and idiosyncratic drug reaction. It is characterized by a sudden loss of body temperature control, renal and respiratory failure, muscle rigidity, loss of consciousness and impairment of autonomic nervous system. Although NMS was previously associated with the use of classical high-potency neuroleptics, cases have started to emerge with atypical neuroleptics. This article discusses the first case of NMS in a child, induced by the use of risperidone, olanzapine and quetiapine.
Aboraya A , Schumacher J , Abdalla E , Lepage J , McGhee M , Butcher D , Griffin H , Shahda M (2002) Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia . W V Med J98: 63-65
2.
Addonizio G , Susman V L (1987) ECT as a treatment alternative for patients with symptoms of neuroleptic malignant syndrome . J Clin Psychiatry48: 102-105
3.
Bajjoka I , Patel T , O’Sullivan T (1997) Risperidone-induced neuroleptic malignant syndrome: a case report . Ann Emerg Med30(5): 698-700
4.
Beasley Jr, C MTollfson G D , Tran P D (1997) Efficacy of olanzapine: an overview of pivotal trials . J Clin Psychiatry58 (Suppl. 10): 7-12
5.
Bottlender R , Jager M , Hofschuster E , Dobmeier P , Moller H J (2002) Three episodes in one patient . Pharmacopsychiatry35: 119-121
6.
Bymaster F D , Colligaro D O , Flacone J F (1996) Radio receptor binding profile of the atypical antipsychotic olazapine . Neuropsychopharmacology14: 87-96
7.
Caroff S N , Mann S C (1988) Neuroleptic malignant syndrome . Psychopharmacol Bull24: 24-29
8.
Caroff S N , Mann S C (1993) Neuroleptic malignant syndrome . Psychiatr Ann77: 185-202
9.
Casey D E (1996) Seroquel: preclinical and clinical findings of a new atypical antipsychotic . Exp Opin Invest Drugs5: 939-957
10.
David M , Remy C (1998) Case report: possible neuroleptic malignant syndrome associated with olanzapine . J Clin Psychopharmacol18(6): 485-486
11.
Donna W , Steven E S , Joseph P (2000) Nonextrapyramidal side effects of novel antipsychotics . Curr Opin Psychiatry13(1): 45-50
12.
Filice G A , McDougall B C , Ercan-Fang N (1998) Neuroleptic malignant syndrome associated with olanzapine . Ann Pharmacother32: 158-1159
13.
Gram L F (2002) Neuroleptic malignant syndrome in the treatment with the new, atypical antipsychotic agents, risperidone and olanzapine . Ugeskr Laeger162: 1914-1915
14.
Gratz S S , Simpson G M (1994) Neuroleptic malignant syndrome . Diagnosis, epidemiology and treatment. CNS Drugs2: 429-439
15.
Hasan S , Buckley P (1998) Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique . Am J Psychiatry155: 1113-1116
16.
Jibson M D , Tanson R (1998) New atypical antipsychotic medications . J Psychiat Res32: 215-222
17.
Kara gianis J L , Phillips L C , Hogan K P , Le Drew K K (1999) Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature . Ann Pharmacother33: 623-630
18.
Kellam A M P (1987) The neuroleptic malignant syndrome, so-called: a survey of the world literature . Br J Psychiatry150: 752-759
19.
Keyser D L , Rodnitzky R L (1991) Neuroleptic malignant syndrome in Parkinson’s disease after withdrawal or duration of dopaminergic therapy . Arch Intern Med14: 794-796
20.
Knezevic W , Mastaglia F , Lefroy R (1984) Neuroleptic malignant syndrome . Med J Aust140: 28-30
21.
Latz S , McCracken J (1992) Neuroleptic malignant syndrome in children and adolescents: two case reports and a warning . J Child Adolesc Psychopharmacol2: 123-129
22.
Mills K C (1993) Serotonin toxicity: a comprehensive review of emergency medicine . Top Emerg Med15: 54-73
23.
Nopoulos D , Flaum M , Miller D D (1990) Atypical neuroleptic malignant syndrome with an atypical neuroleptic: clozapine induced neuroleptic malignant syndrome without rigidity . Ann Clin Psychiatr2: 2251-2253
24.
Pearlman C A (1986) Neuroleptic malignant syndrome . J Clin Psychopharmacol6: 257-273
25.
Robb A S , Chang W , Lee H K , Cook M S (2002) Risperidone-induced neuroleptic malignant syndrome in an adolescent [Case study] . J Child Adolesc Psychopharmacol10: 327-330
26.
Saller C F , Salama A I (1993) Seroquel: biochemical profile of a potential atypical antipsychotic . Psychopharmacology112: 285-292
27.
Shalev A , Muniz H (1986) The neuroleptic malignant syndrome: agent and last interaction . Acta Psychiatry Scand73: 337-347
28.
Stanley A K , Hunter J (2000) Possible neuroleptic malignant syndrome with quetiapine . Br J Psychiatry176: 497
29.
Steingard R , Khan A , Gonzalez A , Herzog D (1992) Neuroleptic malignant syndrome: review of experience with children and adolescents . J Child Adolesc Psychopharmacol2: 183-198
30.
Stewart F (2002) Pharmacology of atypical antipsychotics . Clin Neuropharmacol25(3): 153-157
31.
Tarshy D , Baldessarini R J , Tarazi F T (2002) Effects of newer antipsychotics on extrapyramidal function . CNS Drugs16: 23-45
32.
Tsai G , Crisostomo G , Rosenblatt M L , Stern T A (1995) Neuroleptic malignant syndrome associated with clozapine treatment . Ann Clin Psychiatry7: 91-95
33.
Vikram D , Jober R (2000) Quetiapine: a review of its safety in the management of schizophrenia . Drug Safety23: 295-307
34.
Webster P , Wijeratne C (1994) Risperidone-induced neuroleptic malignant syndrome [letter] . Lancet344: 1228-1229
